OPTX:NASDAQSyntec Optics Holdings, Inc. Analysis
Data as of 2026-04-22 - not real-time
$10.53
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Syntec Optics (OPTX) is trading at $10.53, comfortably above its 20‑day ($9.09), 50‑day ($7.70) and 200‑day ($3.74) SMAs, and the MACD has turned bullish, while the RSI sits at a neutral‑to‑bullish 59. These technical signs suggest short‑term upside, and the stock is currently holding above the identified support of $6.45 with a resistance near $12.20.
However, the fundamentals tell a starkly different story: the company posted a negative profit margin of –6.4%, a trailing EPS of –$0.05, and a staggering debt‑to‑equity ratio of 117%, while its price‑to‑book of 39.6× and price‑to‑sales of 13.9× signal severe overvaluation. Recent news of margin expansion and cost reductions hints at operational improvement, but earnings remain in the red and cash flow is thin, leaving the upside heavily constrained by financial risk and extreme price volatility (140% 30‑day swing) and a high beta of 2.93.
However, the fundamentals tell a starkly different story: the company posted a negative profit margin of –6.4%, a trailing EPS of –$0.05, and a staggering debt‑to‑equity ratio of 117%, while its price‑to‑book of 39.6× and price‑to‑sales of 13.9× signal severe overvaluation. Recent news of margin expansion and cost reductions hints at operational improvement, but earnings remain in the red and cash flow is thin, leaving the upside heavily constrained by financial risk and extreme price volatility (140% 30‑day swing) and a high beta of 2.93.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 4/10
Key Factors
- Bullish technical positioning (price above key SMAs, bullish MACD)
- Proximity to strong support level at $6.45
- High short‑term volatility and beta amplifying price swings
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- Severe overvaluation (PB ~40×, PS ~14×) with no earnings
- Heavy debt load (Debt‑to‑Equity >100%) and negative cash conversion
- Limited revenue growth (≈2.5% YoY) despite cost‑reduction headlines
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Sustained earnings deficits and negative ROE/ROA
- Structural mismatch between market price and underlying book value
- Continued exposure to high systematic risk (beta ~3) and extreme price volatility
Key Metrics & Analysis
Financial Health
Revenue Growth2.50%
Profit Margin-6.39%
ROE-17.43%
ROA-1.29%
Debt/Equity116.99
P/B Ratio39.6
Op. Cash Flow$672.6K
Free Cash Flow$33.5K
Industry P/E37.5
Technical Analysis
TrendBullish
RSI59.3
Support$6.45
Resistance$12.20
MA 20$9.09
MA 50$7.70
MA 200$3.74
MACDBullish
VolumeIncreasing
Fear & Greed Index87
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta2.93
Volatility140.62%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.